Aadi Bioscience, Inc.

NASDAQ:AADI

2.05 (USD) • At close March 18, 2025
Bedrijfsnaam Aadi Bioscience, Inc.
Symbool AADI
Munteenheid USD
Prijs 2.05
Beurswaarde 94,891,630
Dividendpercentage 0%
52-weken bereik 1.21 - 3.812
Industrie Biotechnology
Sector Healthcare
CEO Mr. David J. Lennon Ph.D.
Website https://aadibio.com

An error occurred while fetching data.

Over Aadi Bioscience, Inc.

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor

Vergelijkbare Aandelen

Talaris Therapeutics, Inc. logo

Talaris Therapeutics, Inc.

TALS

2.72 USD

Eiger BioPharmaceuticals, Inc. logo

Eiger BioPharmaceuticals, Inc.

EIGR

1.725 USD

Radius Health, Inc. logo

Radius Health, Inc.

RDUS

29.24 USD

Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc.

AKRO

41 USD

Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc.

EWTX

14.84 USD

LianBio logo

LianBio

LIAN

0.319 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)